Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

IMPORTANCE: Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated incr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: O’Brien, Susan M., Jaglowski, Samantha, Byrd, John C., Bannerji, Rajat, Blum, Kristie A., Fox, Christopher P., Furman, Richard R., Hillmen, Peter, Kipps, Thomas J., Montillo, Marco, Sharman, Jeff, Suzuki, Sam, James, Danelle F., Chu, Alvina D., Coutre, Steven E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885180/
https://ncbi.nlm.nih.gov/pubmed/29470582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5604
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados